Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the phar...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Acta pharmacologica Sinica Ročník 43; číslo 12; s. 3130 - 3138
Hlavní autoři:	Qian, Hong-jie, Wang, Yu, Zhang, Meng-qi, Xie, Yuan-chao, Wu, Qing-qing, Liang, Li-yu, Cao, Ye, Duan, Hua-qing, Tian, Guang-hui, Ma, Juan, Zhang, Zhuo-bing, Li, Ning, Jia, Jing-ying, Zhang, Jing, Aisa, Haji Akber, Shen, Jing-shan, Yu, Chen, Jiang, Hua-liang, Zhang, Wen-hong, Wang, Zhen, Liu, Gang-yi
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Singapore Springer Nature Singapore 01.12.2022 Nature Publishing Group Springer Singapore
Témata:	Adverse events Biomedical and Life Sciences Biomedicine COVID-19 Dosage Drug development Immunology Internal Medicine Medical Microbiology Nucleoside analogs Oral administration Pharmacokinetics Pharmacology/Toxicology Safety Severe acute respiratory syndrome coronavirus 2 Vaccine pharmacokinetics SARS-CoV-2 VV116 healthy subjects nucleoside analog safety
ISSN:	1671-4083, 1745-7254, 1745-7254
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!